Stevanato Group SpA (STVN)

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight ManagementJune 8, 2026 6:30 AM
Business Wire The fixed-dose, multi-use pen injector platform features a pull-push mechanism designed to reduce use error while supporting delivery volumes up to 0.75 mL Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608096966/en/Deora™ is Stevanato Group’s multi-use, fixed-dose pen injector designed for subcutaneous drug delivery in therapies such as diabetes and weight management. Featuring an intuitive pull-push mechanism, the device simplifies dose administration by eliminating the need for manual dose selection: users pull to set the dose and push to inject, supporting consistent delivery across multiple administrations. The platform accommodates fixed-dose volumes up to 0.75 mL and is compatible with standard 1.5 mL and 3 mL cartridges, offering flexibility across a range of therapeutic applications. Engineered with patient usability in mind, Deora™ provides tactile, visual, and audible feedback during operation, helping reduce common sources of use error. Its architecture is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing for pharmaceutical partners Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism for dose setting and delivery: the user pulls to set the dose, then pushes to inject. This intuitive sequence eliminates the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations. The platform is compatible with standard 1.5 mL and 3 mL cartridges and accommodates fixed-dose volumes up to 0.75 mL. “With Deora™, we are broadening our product offering in therapeutic areas experiencing strong global demand and favorable market momentum,” said Michele Monico, President of Drug Delivery Systems and In Vitro Diagnostics at Stevanato Group. "We believe there is space for a simple, multi-use device that enhances the patient experience while simultaneously reducing the pressure on supply chain scale-up. Our belief has been supported by early customer interest, and we are providing our pharmaceutical partners with evaluation units to support early-stage testing and development activities.” The device architecture provides flexibility across multiple fixed-dose configurations while minimizing the need for design changes across variants. In addition, it is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing. “Deora™ further expands Stevanato Group’s proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format,” added Michele Monico. “Customers can now choose from different hand-held device platforms – Alina®, Aidaptus®, and Deora™ – to address a broad range of therapeutic needs.” Deora™ leverages Stevanato Group’s established manufacturing capabilities, with production aligned to support future commercialization. Drawing on its end-to-end expertise across glass manufacturing, analytical services, and device engineering, Stevanato Group offers fully integrated solutions that can simplify development for pharmaceutical partners. Together, these characteristics position Deora™ as a platform intended to support partners as they advance early development programs and prepare for future scale-up. About Stevanato Group Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com. Forward-Looking Statements This press release may include forward-looking statements. The words “strong”, “experiencing”, “believe”, “are providing”, “position”, “advance”, “intended”, “prepare”, “future”, and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the investments the Company expects to receive, the expansion of manufacturing capacity, the Company’s plans regarding its presence in the U.S. market, business strategies, the Company’s capacity to meet future market demands and support preparedness for future public health emergencies, and results of operations. The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements. View source version on businesswire.com: https://www.businesswire.com/news/home/20260608096966/en/ Media
Caterina Tripepi
caterina.tripepi@stevanatogroup.com
Barabino & Partners for Stevanato Group
stevanato.intl@barabino.it Investor Relations
Lisa Miles
lisa.miles@stevanatogroup.com
Giacomo Guiducci
giacomo.guiducci@stevanatogroup.com Original: Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders’ MeetingJune 3, 2026 5:45 PM
Business Wire All Resolutions Proposed to Shareholders Passed Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that all resolutions proposed to the shareholders at the Ordinary and Extraordinary Meeting of Shareholders (“Shareholders’ Meeting”) held virtually on May 26, 2026, have passed. Details of the resolutions submitted to, and approved by, the Shareholders’ Meeting are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company’s corporate website at https://ir.stevanatogroup.com/. Shareholders approved, among other things, the annual financial statements for the financial year ended on December 31, 2025 and the allocation of annual net profits for the year, including a distribution of dividends in the amount of EUR 0.054 for each outstanding Class A and ordinary share of the Company, net of the treasury shares. A Board of Directors consisting of eleven members was appointed, comprising Franco Stevanato, Sergio Stevanato, Madhavan Balachandran, William Federici, Karen Flynn, Sue Jean Lin, Elisabetta Magistretti, Donald Eugene Morel Jr., Luciano Santel and Alvise Spinazzi (who were also members of the previous board), together with Peter Soelkner (who is newly appointed). In addition, shareholders approved, among other things, the compensation of the members of the Board of Directors and of the members of the Audit Committee, as well as the appointment of PricewaterhouseCoopers S.p.A. as external auditor for the auditing of the Company’s financial statements and consolidated financial statements and the performance of the further tasks and activities to be conducted in compliance with Italian and U.S. laws and regulations for the financial years ending on December 31, 2026, December 31, 2027, and December 31, 2028. Further, shareholders granted to the Board of Directors – due to the expiration of the existing authorizations – a new authorization for the purchase and the disposal of ordinary and Class A treasury shares for the period and purposes indicated in the explanatory report. In the extraordinary session, shareholders approved amendments to Articles 7.6, 16 and 23 of the Company’s By-laws, aimed at, among other things, (i) facilitating the exercise of corporate rights by the beneficial shareholders of ordinary shares, (ii) introducing the possibility for the outgoing Board of Directors to submit a slate of candidates for the appointment of the new Board of Directors, and (iii) granting the Board of Directors greater flexibility in the appointment of members of the Audit Committee. Further information regarding the Shareholders’ Meeting is available on the investors’ section of Stevanato Group’s corporate website at https://ir.stevanatogroup.com/, including the full text of the Shareholders’ Meeting notice, explanatory report and other Shareholders’ Meeting materials. Shareholders may request a hard copy of Shareholders’ Meeting materials, free of charge, by emailing legal@stevanatogroup.com. About Stevanato Group Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Certain statements contained in this press release, including statements regarding the appointment of the new Board of Directors and the accomplishment of the Company’s future goals, are forward-looking statements based on Stevanato Group’s current assumptions, expectations and beliefs and involve substantial risks and uncertainties that may cause results, performance or achievement to materially differ from those expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties, including market conditions and Stevanato Group’s results of operations. As such, the reader should not place undue reliance on these forward-looking statements, as there can be no assurances that the plans, initiatives or expectations upon which they are based will occur. For a description of additional factors that could cause the Company’s future results to differ from those expressed in any such forward-looking statements, refer to the risk factors discussed under “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 4, 2026. All forward-looking statements in this press release are based on information currently available to Stevanato Group and speak only as of the date of this press release, and Stevanato Group assumes no obligation to update these forward-looking statements in light of new information or future events, except as may be required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260603221961/en/ Media Stevanato Group
media@stevanatogroup.com Investor Relations
Lisa Miles
lisa.miles@stevanatogroup.com Original: Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders’ Meeting

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026May 7, 2026 6:30 AM
Business Wire - The Company Maintains Fiscal 2026 Guidance - Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2026. First Quarter of 2026 Highlights (comparisons to prior-year period) For the first quarter of 2026, revenue increased 7% (10% on a constant currency basis) to €273.6 million, with high-value solutions representing 47% of total revenue. Gross profit margin increased 30 basis points to 27.5%. Adjusted EBITDA margin increased 150 basis points to 23.9%. Diluted earnings per share were €0.10, and adjusted diluted earnings per share were €0.11. The Company is maintaining its fiscal 2026 guidance and still expects revenue in the range of €1.26 billion to €1.29 billion, adjusted EBITDA in the range of €331.8 million to €346.9 million, and adjusted diluted EPS in the range of €0.59 to €0.63. First Quarter 2026 Results For the first quarter of 2026, total revenue increased 7% year-over-year (10% on a constant currency basis) to €273.6 million, driven by a 13% revenue increase (16% on a constant currency basis) from the Company's Biopharmaceutical and Diagnostic Solutions (BDS) Segment, which offset the revenue decline from the Engineering Segment. Revenue from high-value solutions increased 17%, year-over-year, to €128.6 million, and represented 47% of total revenue for the first quarter of 2026. In the first quarter of 2026, gross profit margin increased 30 basis points to 27.5% driven by: (i) the ongoing improvements in Fishers and Latina as the new facilities continue to scale, (ii) an increase in high-value solutions, and (iii) improved marginality in the Engineering Segment. These positive trends were partially offset by the expected higher depreciation and the effects of foreign currency translation in the first quarter of 2026. Operating profit margin improved 70 basis points to 14.2%. Net profit was €28.0 million for the first quarter of 2026, with diluted earnings per share of €0.10. For the first quarter of 2026, adjusted net profit increased to €29.6 million and adjusted diluted earnings per share increased to €0.11, compared with €0.10 for the same period last year. For the first quarter of 2026, adjusted EBITDA increased to €65.5 million, and adjusted EBITDA margin improved 150 basis points to 23.9%, compared with the same period last year. Franco Stevanato, Chief Executive Officer, commented, "The first quarter was a solid start to 2026, highlighted by strong momentum in the BDS Segment which delivered 16% growth at constant currency rates, driven by revenue increases across most product categories in both high-value and standard products. As expected, higher depreciation tempered gross profit margins in the quarter but results also reflect financial improvements in Fishers and Latina as we scale production, which in turn is driving the increase in high-value solutions. Revenue from biologics, which is our fastest growing end market, increased 15%, compared to the prior-year period, driven by GLP1s which accounted for approximately 21% to 22% of total Company revenue. Our success in this blockbuster treatment class demonstrates the trust and reliability that customers place on Stevanato Group to deliver high quality products at scale for their most valuable drug assets." Biopharmaceutical and Diagnostic Solutions (BDS) Segment Revenue grew 13% (16% on a constant currency basis) to €249.0 million for the first quarter of 2026, compared with the same period last year, driven by growth in high value and standard products. In the first quarter of 2026, revenue from high-value solutions increased 17% to €128.6 million, and represented 52% of BDS Segment revenue, driven predominantly by high-performance syringes and, to a lesser extent, EZ-fill® vials. Revenue from other containment and delivery solutions increased 9% to €120.3 million, compared with the same period last year, driven mostly by standard syringes and cartridges, which offset a lower revenue from IVD services. For the first quarter of 2026, gross profit increased €1.2 million driven by the ramp up in Fishers and Latina and the favorable mix shift in high-value solutions. This was partially offset by: (i) higher depreciation, which was the largest headwind to gross profit, as more manufacturing lines are put into commercial service, (ii) the unfavorable effects of foreign currency, (iii) lower revenue and profit from an accretive pilot project with an industry-leading customer for large-batch, Not for Human Use (NFHU) fill and finish services, which did not recur in the first quarter of 2026, and (iv) the unfavorable impact from tariffs. As a result, gross profit margin decreased 300 basis points to 28.3%. Engineering Segment Revenue from the Engineering Segment decreased 31% to €24.6 million for the first quarter of 2026, compared with the same period last year, driven by lower revenue from glass converting and assembly manufacturing, which offset growth in pharmaceutical visual inspection. For the first quarter of 2026, gross profit margin for the Engineering Segment increased 460 basis points to 15.3%, compared with the same period last year, as the Company begins to realize the benefits from the actions taken under its business optimization plan. This includes right-sizing operations and an improved labor cost structure which led to better financial performance in the Company's Denmark operations. While actions under the optimization plan are starting to gain traction, the Company remains cautious given the current slow pace of orders. Balance Sheet and Cash Flow As of March 31, 2026, the Company had cash and cash equivalents of €111.7 million, and net debt of €337.7 million. For the first quarter of 2026, capital expenditures totaled €67.6 million, as the Company continues to increase capacity in its new manufacturing facilities in Indiana and Italy. For the three-months ended March 31, 2026, cash flow from operating activities was €75.5 million and cash used for the purchase of property, plant, and equipment, and intangible assets totaled €70.7 million. As a result, the Company generated €5.5 million of positive free cash flow for the first quarter of 2026. The Company believes that it has adequate liquidity to fund its strategic priorities over at least the next twelve months through a combination of cash on hand, cash generated from operations, available credit lines, and the ability to access additional financing. 2026 Guidance The Company is maintaining its fiscal 2026 guidance and continues to expect: Revenue in the range of €1.26 billion to €1.29 billion; Adjusted EBITDA in the range of €331.8 million to €346.9 million; and Adjusted diluted EPS in the range of €0.59 to €0.63. Franco Stevanato concluded, "Looking ahead, our strategic investments and focus on high-value, scalable solutions position us to capitalize on the accelerating growth in biologics and injectable therapies. With our operational flexibility and competitive leadership in core product categories, we are confident in our ability to support customers and drive future success." Conference call: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 7, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the “Financial Results” page under the Investor Relations section of the Company's website. Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link: Pre-registration for STVN Q1 2026 earnings webcast. Webcast: A live, listen-only webcast of the call will be available at the following link: STVN Q1 2026 webcast. Dial in: Those who are unable to pre-register may dial in by calling: Italy: +39 02 802 09 11 United Kingdom: +44 1 212 818004 United States: +1 718 705 8796 United States Toll Free: +1 855 265 6958 Questions during the call: Participants who wish to ask questions during the call should use the HD webphone link: STVN Q1 2026 Link for Questions Replay: The webcast will be archived for three months on the Company’s Investor Relations section of its website. Forward-Looking Statements This press release may include forward-looking statements. The words "expects," "scale," "driving," "increase," "begins," "are starting," "remains," "continues," "believes," "expect," "position," "accelerating," "drive," and other similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's future financial performance, including revenue, operating expenses and ability to maintain profitability, and operational and commercial capabilities; the Company's expectations regarding the development of the industry and the competitive environment in which it operates; the expansion of the Company's plants and sites, and our expectations related to our capacity expansion; the global supply chain and the Company's committed orders; customer demand; the success of the Company's initiatives to optimize the industrial footprint, harmonize processes and enhance supply chain and logistics strategies; the Company's geographical and industrial footprint; and the Company's goals, strategies, and investment plans. The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future, and may cause the actual results, performance, or achievements of the Company to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as conditions in the U.S. capital markets, negative global and domestic economic and political conditions, inflation, trade war and global tariff policies, the impact of the conflict between Russia and the Ukraine, the evolving events in Israel and Gaza, the Iran regional conflict (including U.S. participation), supply chain and logistical challenges and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the geopolitical, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. For a description of the risks that could cause the Company’s future results to differ from those expressed in any such forward looking statements, refer to the risk factors discussed in our most recent annual report on Form 20-F, and our most recent filings with the U.S. Securities and Exchange Commission. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the Company assumes no obligation to update any such forward-looking statements. Non-GAAP Financial Information This press release contains non-GAAP financial measures. Please refer to the tables included in this press release for a reconciliation of non-GAAP financial measures. Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, Adjusted Income Taxes, Adjusted Net Profit, Adjusted Diluted EPS, CAPEX, Free Cash Flow, Net Cash/(Debt), and Capital Employed. The Company believes that these non-GAAP financial measures provide useful and relevant information regarding its performance and improve its ability to assess our financial condition. While similar measures are widely used in the industry in which the Company operates, the financial measures it uses may not be comparable to other similarly titled measures used by other companies, nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS. About Stevanato Group Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com. Consolidated Income Statement (Amounts in € millions, except per share data)       For the three months       ended March 31,               2026     %     2025     %                             Revenue     273.6       100.0 %     256.6       100.0 % Costs of sales     198.4       72.5 %     186.7       72.8 % Gross Profit     75.2       27.5 %     69.9       27.2 % Other operating Income     1.4       0.5 %     1.1       0.4 % Selling and Marketing Expenses     6.7       2.5 %     6.0       2.3 % Research and Development Expenses     5.8       2.1 %     5.9       2.3 % General and Administrative Expenses     25.3       9.2 %     24.5       9.6 % Operating Profit     38.7       14.2 %     34.6       13.5 % Finance Income     3.4       1.2 %     6.0       2.2 % Finance Expense     2.9       1.0 %     5.5       2.1 % Profit Before Tax     39.2       14.3 %     35.1       13.7 % Income Taxes     11.2       4.1 %     8.6       3.3 % Net Profit     28.0       10.2 %     26.5       10.3 % Earnings per share                         Basic earnings per ordinary share     0.10             0.10         Diluted earnings per ordinary share     0.10             0.10                                                             Average shares outstanding     273.0             272.9         Average shares assuming dilution     273.0             272.9         Reported Segment Information (Amounts in € millions)       For the three months ended March 31, 2026       Biopharmaceutical
and Diagnostic
Solutions     Engineering     Adjustments,
eliminations
and
unallocated
items     Consolidated                             External Customers     249.0       24.6       —       273.6   Inter-Segment     0.3       31.0       (31.2 )     —   Revenue     249.2       55.6       (31.2 )     273.6                             Gross Profit     70.5       8.5       (3.9 )     75.2   Gross Profit Margin     28.3 %     15.3 %           27.5 %                           Operating Profit     44.1       3.7       (9.1 )     38.7   Operating Profit Margin     17.7 %     6.6 %           14.2 %     For the three months ended March 31, 2025       Biopharmaceutical
and Diagnostic
Solutions     Engineering     Adjustments,
eliminations
and
unallocated
items     Consolidated                             External Customers     220.8       35.7       —       256.6   Inter-Segment     0.4       42.4       (42.8 )     —   Revenue     221.2       78.2       (42.8 )     256.6                             Gross Profit     69.3       8.3       (7.7 )     69.9   Gross Profit Margin     31.3 %     10.7 %           27.2 %                           Operating Profit     41.5       3.7       (10.6 )     34.6   Operating Profit Margin     18.8 %     4.7 %           13.5 % Cash Flow (Amounts in € millions)       For the three months
ended March 31,       2026     2025   Cash flow from operating activities     75.5       99.8   Cash flow used in investing activities     (70.4 )     (70.7 ) Cash flow used in financing activities     (24.9 )     (35.7 ) Net change in cash and cash equivalents     (19.8 )     (6.6 ) Non-GAAP Financial Information This press release contains non-GAAP financial measures. Please refer to "Non-GAAP Financial Information" and the tables included in this press release for a reconciliation of non-GAAP financial measures. Reconciliation of Revenue to Constant Currency Revenue (Amounts in € millions)   Three months ended March 31, 2026   Biopharmaceutical
and
Diagnostic
Solutions     Engineering     Consolidated   Reported Revenue (IFRS GAAP)     249.0       24.6       273.6   Effect of changes in currency translation rates     8.1       —       8.1   Constant Currency Revenue (Non-IFRS GAAP)     257.0       24.6       281.7   Reconciliation of EBITDA (Amounts in € millions)       For the three months
ended March 31,     Change       2026     2025     %   Net Profit     28.0       26.5       5.7 % Income Taxes     11.2       8.6       30.4 % Finance Income     (3.4 )     (6.0 )     (43.6 )% Finance Expenses     2.9       5.5       (47.8 )% Operating Profit     38.7       34.6       11.9 % Depreciation and Amortization and Impairment of PPE     24.7       20.6       19.5 % EBITDA     63.4       55.3       14.7 % Calculation of Net Profit Margin, Operating Profit Margin, Adjusted EBITDA Margin and Adjusted Operating Profit Margin (Amounts in € millions)       For the three months
ended March 31,       2026     2025   Revenue     273.6       256.6   Net Profit Margin (Net Profit/ Revenue)     10.2 %     10.3 % Operating Profit Margin (Operating Profit/ Revenue)     14.2 %     13.5 % Adjusted EBITDA Margin (Adjusted EBITDA/ Revenue)     23.9 %     22.4 % Adjusted Operating Profit Margin (Adjusted Operating Profit/ Revenue)     14.9 %     14.3 % Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit, and Diluted EPS (Amounts in € millions, except per share data)   Three months ended March 31, 2026   EBITDA     Operating
Profit     Income
Taxes (3)     Net Profit     Diluted EPS
(EUR)   Reported     63.4       38.7       11.2       28.0       0.10   Adjusting items:                               Start-up costs new plants (1)     1.8       1.8       0.5       1.3       0.00   Restructuring and related charges (2)     0.3       0.3       0.1       0.2       0.00   Adjusted     65.5       40.8       11.8       29.6       0.11   Adjusted Margin     23.9 %     14.9 %                   Three months ended March 31, 2025   EBITDA     Operating
Profit     Income
Taxes (3)     Net Profit     Diluted EPS
(EUR)   Reported     55.3       34.6       8.6       26.5       0.10   Adjusting items:                               Start-up costs new plants (1)     0.8       0.8       0.2       0.6       0.00   Restructuring and related charges (2)     1.3       1.3       0.3       1.0       0.00   Adjusted     57.4       36.7       9.1       28.1       0.10   Adjusted Margin     22.4 %     14.3 %                     (1) During the three months ended March 31, 2026, and the three months ended March 31, 2025, the Group recorded €1.8 million and €0.8 million, respectively, of start-up costs for the new plants in Fishers, Indiana, United States, and in Latina, Italy. These costs are primarily related to labor costs for training and travel of personnel who are in the learning and development phase and not active in the manufacturing of products.   (2) During the three months ended March 31, 2026, and the three months ended March 31, 2025, the Group recorded €0.3 million and €1.3 million, respectively, of restructuring and related charges among cost of sales, and general and administrative expenses. These charges mainly relate to (i) employee costs arising from the reorganization of certain business functions across the Group and (ii) employee costs associated with a business reorganization and optimization plan in Denmark.   (3) The income tax adjustment is calculated by multiplying the applicable nominal tax rate to the adjusting items. Capital Employed (Amounts in € millions)     As of March 31,
2026     As of December 31,
2025                 - Goodwill and intangible assets     86.5       86.8   - Right of use assets     15.2       12.4   - Property, plant, and equipment     1,451.0       1,391.5   - Financial assets - investments FVTPL     0.1       0.2   - Other non-current financial assets     5.5       5.5   - Deferred tax assets     110.2       103.9   Non-current assets excluding FV of derivative financial instruments     1,668.6       1,600.3                 - Inventories     294.4       268.2   - Contract assets     165.8       180.5   - Trade receivables     278.5       302.7   - Trade payables     (254.4 )     (263.3 ) - Advances from customers     (42.4 )     (33.4 ) - Non-current advances from customers     (92.2 )     (98.8 ) - Contract liabilities     (11.6 )     (10.4 ) Trade working capital     338.0       345.4                 - Tax receivables and other receivables     53.7       50.6   - Current financial receivables - rent to buy agreement     8.7       8.6   - Tax payables and other current liabilities     (121.2 )     (100.8 ) - Current provisions     (2.3 )     (4.4 ) Net working capital     276.8       299.3                 - Deferred tax liabilities     (14.6 )     (13.3 ) - Employees benefits     (6.8 )     (6.8 ) - Non-current provisions     (2.5 )     (3.2 ) - Other non-current liabilities     (52.9 )     (52.1 ) Total non-current liabilities and provisions     (76.8 )     (75.4 )               Capital employed     1,868.6       1,824.2                 Net (debt) /cash     (337.7 )     (337.7 )               Total Equity     (1,530.8 )     (1,486.5 )               Total equity and net (debt)/ cash     (1,868.6 )     (1,824.2 )               Free Cash Flow (Amounts in € millions)       For the three months
ended March 31,       2026     2025   Net cash flow from operating activities     75.5       99.8   Interest paid     0.8       1.4   Interest received     (0.5 )     (0.9 ) Purchase of property, plant, and equipment     (66.3 )     (70.4 ) Proceeds from sale of property, plant, and equipment     0.2       1.1   Refund of capitalized costs of property, plant, and equipment     0.1       —   Purchase of intangible assets     (4.5 )     (1.4 ) Free Cash Flow     5.5       29.7   Net (Debt) / Net Cash (Amounts in € millions)       As of March 31,     As of December 31,       2026     2025   Non-current financial liabilities     (323.8 )     (347.4 ) Current financial liabilities     (128.3 )     (123.5 ) Other non-current financial assets - Fair value of derivatives financial instruments     0.9       0.3   Other current financial assets other than financial receivables for rent to buy agreement     1.8       2.2   Cash and cash equivalents     111.7       130.6   Net (Debt)/ Cash     (337.7 )     (337.7 ) CAPEX (Amounts in € millions)     For the three months
ended March 31,     Change     2026     2025     €   Addition to Property, plant, and equipment   66.4       68.3       (1.9 ) Addition to Intangible Assets   1.2       1.4       (0.2 ) CAPEX   67.6       69.7       (2.1 ) Reconciliation of 2026 Guidance* Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS (Amounts in € millions, except per share data)       Revenue   EBITDA   Operating
Profit   Net Profit   Diluted EPS
(EUR) Reported   1,260.0 - 1,290.0   317.7 - 332.9   212.7 - 227.8   149.6 - 160.7   0.55 - 0.59 Adjusting items:                     Start-up costs new plants       14.1   14.1   10.3   0.04 Adjusted   1,260.0 - 1,290.0   331.8 - 346.9   226.8 - 241.9   159.9 - 171.0   0.59 - 0.63 *Amounts may not add due to rounding   View source version on businesswire.com: https://www.businesswire.com/news/home/20260507757726/en/ Media
Caterina Tripepi
caterina.tripepi@stevanatogroup.com Investor Relations
Lisa Miles
lisa.miles@stevanatogroup.com Giacomo Guiducci
giacomo.guiducci@stevanatogroup.com Original: Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026

Stevanato Group to Participate in Three Upcoming Investor ConferencesMay 4, 2026 5:45 PM
Business Wire Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences: Tuesday, May 12, at 8:00 a.m. (PT) - Bank of America Global Healthcare Conference in Las Vegas, NV Tuesday, June 2, at 2:40 - 3:10 p.m. (CT) – William Blair Growth Stock Conference in Chicago, IL Thursday, June 4, at 9:55 - 10:25 a.m. (EDT) – Jefferies Healthcare Conference in New York, NY A live webcast for each event will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section. A replay of the webcast will be available for approximately 90 days after the event. About Stevanato Group Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value-added solutions to clients. For more information, please visit: www.stevanatogroup.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260504199153/en/ Media
Stevanato Group
media@stevanatogroup.com Investor Relations
Lisa Miles
lisa.miles@stevanatogroup.com Giacomo Guiducci
giacomo.guiducci@stevanatogroup.com Original: Stevanato Group to Participate in Three Upcoming Investor Conferences

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare ForumMarch 12, 2026 4:45 PM
Business Wire
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Virtual Healthcare Forum taking place on Tuesday, March 17 and Wednesday, March 18, 2026.


The Company will present on Tuesday, March 17, at 9.45-10.20 a.m. (ET). A live webcast will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section. A replay of the webcast will be available for approximately 90 days after the event.


About Stevanato Group


Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value-added solutions to clients.


For more information, please visit: www.stevanatogroup.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260312286247/en/
Media

Stevanato Group

media@stevanatogroup.com


Investor Relations

Lisa Miles

lisa.miles@stevanatogroup.com


Original: Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum

Stevanato Group shares jump nearly 17% after strong fourth-quarter resultsMarch 4, 2026 8:15 AM
IH Market News
Stevanato Group S.p.A. (NYSE:STVN) reported fourth-quarter results on Wednesday that came in ahead of analyst expectations.Shares of the company surged 16.70% in after-hours trading following the announcement, as investors responded to continued strength in its high-value solutions segment.The Italian provider of drug containment and delivery systems reported adjusted diluted earnings per share of €0.18 for the fourth quarter, slightly above the analyst consensus estimate of €0.17.Revenue rose 5% year over year — or 7% at constant exchange rates — to €346.5 million, exceeding the consensus estimate of €333.79 million and increasing from €330.6 million in the same period last year. High-value solutions accounted for 49% of total revenue, reaching a record €171.4 million.The results were supported by a 10% increase in revenue within the company’s Biopharmaceutical and Diagnostic Solutions division. Gross profit margin expanded by 120 basis points to 30.9%, while adjusted EBITDA margin improved by 70 basis points to 28.2%.Franco Stevanato, Chief Executive Officer, commented, “We concluded fiscal year 2025 with another solid quarter that led to positive full-year performance underpinned by strong top-line growth, a favorable mix of high value solutions, and expanded margins.”For fiscal 2026, Stevanato expects adjusted diluted earnings per share to range between €0.59 and €0.63, with a midpoint of €0.61, slightly below the analyst consensus forecast of €0.64.The company anticipates revenue of between €1.26 billion and €1.29 billion, implying a midpoint of €1.275 billion, broadly aligned with the consensus estimate of €1.28 billion. Adjusted EBITDA is projected in a range of €331.8 million to €346.9 million.Stevanato also noted that GLP-1 treatments accounted for roughly 19% to 20% of total revenue in 2025, highlighting the company’s growing presence in the expanding biologics market.Stevanato Group stock price

Original: Stevanato Group shares jump nearly 17% after strong fourth-quarter results

Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded MarginsMarch 4, 2026 6:30 AM
Business Wire
- Establishes Fiscal 2026 Guidance -


Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2025.


Fourth Quarter and Full Year 2025 Highlights (comparisons to prior-year periods)



For the fourth quarter of 2025, revenue increased 5% (7% on a constant currency basis) to €346.5 million, and high-value solutions represented 49% of total revenue.



Gross profit margin increased 120 basis points to 30.9%, and adjusted EBITDA margin increased 70 basis points to 28.2%, for the fourth quarter of 2025.



Diluted earnings per share were €0.17, and adjusted diluted earnings per share were €0.18 for the fourth quarter of 2025.



For the fiscal year 2025, revenue increased 7% (9% on a constant currency basis) to €1.186 billion, and high-value solutions represented 46% of total revenue.



Gross profit margin increased 160 basis points to 29.0%, and adjusted EBITDA margin increased 160 basis points to 25.1% for the fiscal year 2025.



For the fiscal year 2025, diluted earnings per share grew 19% to €0.51, and adjusted diluted earnings per share increased 13% to €0.54.



The Company is establishing its fiscal 2026 guidance. The Company expects revenue in the range of €1.26 billion to €1.29 billion, adjusted EBITDA in the range of €331.8 million to €346.9 million, and adjusted diluted EPS in the range of €0.59 to €0.63.



Fourth Quarter 2025 Results


For the fourth quarter of 2025, total revenue increased 5% year-over-year (7% on a constant currency basis) to €346.5 million, driven by a 10% (13% on a constant currency basis) revenue increase from the Company's Biopharmaceutical and Diagnostic Solutions (BDS) Segment, which offset the anticipated revenue decline from the Engineering Segment. Revenue from high-value solutions increased 31%, year-over-year, to a record €171.4 million, representing 49% of total revenue for the fourth quarter of 2025.


In the fourth quarter of 2025, strong performance in the BDS Segment led to a 120 basis-point increase in gross profit margin to 30.9%, compared with the same period last year, and operating profit margin was 20.2%, consistent with the same period last year.


Net profit was €47.6 million, with diluted earnings per share of €0.17, for the fourth quarter of 2025, and adjusted net profit was €49.8 million with diluted earnings per share of €0.18. For the fourth quarter of 2025, adjusted EBITDA increased to €97.7 million, and the adjusted EBITDA margin improved 70 basis points to 28.2%, compared with the same period last year.


Franco Stevanato, Chief Executive Officer, commented, "We concluded fiscal year 2025 with another solid quarter that led to positive full-year performance underpinned by strong top-line growth, a favorable mix of high value solutions, and expanded margins. Biologics remain an important tailwind and in 2025 GLP1s represented approximately 19% to 20% of total Company revenue. There’s no doubt that we have been successful in winning our fair share of the GLP1 market. This success is rooted in our long history of being a trusted partner to customers, our global footprint which provides supply chain security, and the quality of our products which have characteristics that resonate with our customers."


Biopharmaceutical and Diagnostic Solutions (BDS) Segment


Revenue grew 10% (13% on a constant currency basis) to €307.1 million for the fourth quarter of 2025, compared with the same period last year, driven by a 31% increase from high-value solutions to €171.4 million, which represented 56% of BDS Segment revenue. Revenue from other containment and delivery solutions decreased 9% to €135.7 million, compared with the same period last year, due to a decline in certain lower-value bulk products, as the Company transitions to a larger portfolio of high-value products aligned with its strategic investments.


For the fourth quarter of 2025, gross profit margin increased 50 basis points to 31.6%, and operating profit margin rose 50 basis points to 23.8%, compared with the same period last year, driven by: (i) a favorable mix of high value solutions, (ii) improvements as the Company scales commercial production in its new facilities, which remain dilutive to the corporate margin, and (iii) an improved vial market which led to higher vial production and better utilization. These positive trends were partially offset by the unfavorable impact from foreign currency translation and tariffs.


Engineering Segment


As expected, revenue from the Engineering Segment decreased 23% to €39.4 million for the fourth quarter of 2025, compared with the same period last year, driven by lower revenue from our glass converting and assembly lines businesses.


For the fourth quarter of 2025, gross profit margin for the Engineering Segment decreased 280 basis points to 15.8%, compared with the same period last year, and continued to be impacted by an unfavorable project mix and a lower volume of new work.


Balance Sheet and Cash Flow


As of December 31, 2025, the Company had cash and cash equivalents of €130.6 million, and net debt of €337.7 million.


For fiscal year 2025, capital expenditures totaled €294.9 million, as the Company continues to increase capacity in its new manufacturing facilities in Indiana and Italy. Cash flow from operating activities for fiscal year 2025 was €286.1 million. Cash used for the purchase of property, plant, and equipment, and intangible assets totaled €275.1 million. Increased operational cash flow and reduced capital expenditures resulted in €18.4 million of positive free cash flow for the year ended 2025.


The Company believes that it has adequate liquidity to fund its strategic priorities over the next twelve months through a combination of cash on hand, cash generated from operations, available credit lines, and the ability to access additional financing.


2026 Guidance


The Company is establishing its fiscal 2026 guidance and expects:



Revenue in the range of €1.26 billion to €1.29 billion;



Adjusted EBITDA in the range of €331.8 million to €346.9 million; and



Adjusted diluted EPS in the range of €0.59 to €0.63.



Franco Stevanato, Chief Executive Officer, concluded, "We enter 2026 with positive momentum and a clear focus on disciplined execution. We operate in attractive, growing end markets with favorable secular tailwinds. Innovation across the industry continues to advance patient care and we remain mission critical to the delivery of innovative biologics. Biologics are expected to remain our fastest growing end market and a key driver to top-line growth and margin expansion as we continue to move up the value chain. In Latina and Fishers, we expect to increasingly benefit from improved utilization, efficiencies, and operating leverage, as we support our customers with quality and reliability."


Conference call: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Wednesday, March 4, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the “Financial Results” page under the Investor Relations section of the Company's website.


Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link: Pre-registration for STVN Q4 2025 earnings webcast.


Webcast: A live, listen-only webcast of the call will be available at the following link: STVN Q4 2025 webcast.


Dial in: Those who are unable to pre-register may dial in by calling:




Italy:






+39 02 802 09 11








United Kingdom:






+44 1 212 818004








United States:






+1 718 705 8796








United States Toll Free:






+1 855 265 6958







Questions during the call: Participants who wish to ask questions during the call should use the HD webphone link: STVN Q4 2025 Link for Questions


Replay: The webcast will be archived for three months on the Company’s Investor Relations section of its website.


Forward-Looking Statements


This press release may include forward-looking statements. The words "establishing," "continued," "remain," "expected," "improved," "transitions," "scales," "believes," "expects," "continues," "growing," "expect," and other similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's future financial performance, including revenue, operating expenses and ability to maintain profitability, and operational and commercial capabilities; the Company's expectations regarding the development of the industry and the competitive environment in which it operates; the expansion of the Company's plants and sites, and our expectations related to our capacity expansion; the global supply chain and the Company's committed orders; customer demand; the success of the Company's initiatives to optimize the industrial footprint, harmonize processes and enhance supply chain and logistics strategies; the Company's geographical and industrial footprint; and the Company's goals, strategies, and investment plans. The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties, and contingencies because they relate to events and depend on circumstances that may or may not occur in the future, and may cause the actual results, performance, or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as conditions in the U.S. capital markets, negative global and domestic economic and political conditions, inflation, trade war and global tariff policies, the impact of the conflict between Russia and the Ukraine, the evolving events in Israel and Gaza, supply chain and logistical challenges and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the geopolitical, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. For a description of the risks that could cause the Company’s future results to differ from those expressed in any such forward looking statements, refer to the risk factors discussed in our most recent annual report on Form 20-F, and our most recent filings with the U.S. Securities and Exchange Commission. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the Company assumes no obligation to update any such forward-looking statements.


Non-GAAP Financial Information


This press release contains non-GAAP financial measures. Please refer to the tables included in this press release for a reconciliation of non-GAAP financial measures.


Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, Adjusted Income Taxes, Adjusted Net Profit, Adjusted Diluted EPS, CAPEX, Free Cash Flow, Net Cash/(Debt), and Capital Employed. The Company believes that these non-GAAP financial measures provide useful and relevant information regarding its performance and improve its ability to assess our financial condition. While similar measures are widely used in the industry in which the Company operates, the financial measures it uses may not be comparable to other similarly titled measures used by other companies, nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS.


About Stevanato Group


Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.




Consolidated Income Statement








(Amounts in € millions, except per share data)








 








 






 






For the three months






 






 






For the years






 








 






 






ended December 31,






 






 






ended December 31,






 








 






 






 






 






 






 






 








 






 






2025






 






 






%






 






 






2024






 






 






%






 






 






2025






 






 






%






 






 






2024






 






 






%






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 








Revenue






 






 






346.5






 






 






 






100.0






%






 






 






330.6






 






 






 






100.0






%






 






 






1,186.3






 






 






 






100.0






%






 






 






1,104.0






 






 






 






100.0






%








Costs of Sales






 






 






239.6






 






 






 






69.1






%






 






 






232.4






 






 






 






70.3






%






 






 






842.4






 






 






 






71.0






%






 






 






801.7






 






 






 






72.6






%








Gross Profit






 






 






106.9






 






 






 






30.9






%






 






 






98.2






 






 






 






29.7






%






 






 






343.9






 






 






 






29.0






%






 






 






302.3






 






 






 






27.4






%








Other Operating Income






 






 






3.5






 






 






 






1.0






%






 






 






5.5






 






 






 






1.7






%






 






 






8.2






 






 






 






0.7






%






 






 






9.1






 






 






 






0.8






%








Selling and Marketing Expenses






 






 






7.9






 






 






 






2.3






%






 






 






5.9






 






 






 






1.8






%






 






 






28.2






 






 






 






2.4






%






 






 






24.9






 






 






 






2.3






%








Research and Development Expenses






 






 






5.8






 






 






 






1.7






%






 






 






5.6






 






 






 






1.7






%






 






 






25.4






 






 






 






2.1






%






 






 






31.7






 






 






 






2.9






%








General and Administrative Expenses






 






 






26.6






 






 






 






7.7






%






 






 






25.4






 






 






 






7.7






%






 






 






99.7






 






 






 






8.4






%






 






 






93.7






 






 






 






8.5






%








Operating Profit






 






 






70.1






 






 






 






20.2






%






 






 






66.8






 






 






 






20.2






%






 






 






198.8






 






 






 






16.8






%






 






 






161.1






 






 






 






14.6






%








Finance Income






 






 






0.3






 






 






 






0.1






%






 






 






5.6






 






 






 






1.7






%






 






 






13.0






 






 






 






1.1






%






 






 






13.5






 






 






 






1.2






%








Finance Expense






 






 






4.6






 






 






 






1.3






%






 






 






7.8






 






 






 






2.4






%






 






 






22.7






 






 






 






1.9






%






 






 






14.3






 






 






 






1.3






%








Profit Before Tax






 






 






65.8






 






 






 






19.0






%






 






 






64.6






 






 






 






19.6






%






 






 






189.1






 






 






 






15.9






%






 






 






160.3






 






 






 






14.5






%








Income Taxes






 






 






18.2






 






 






 






5.3






%






 






 






16.3






 






 






 






4.9






%






 






 






49.3






 






 






 






4.2






%






 






 






42.5






 






 






 






3.9






%








Net Profit






 






 






47.6






 






 






 






13.7






%






 






 






48.3






 






 






 






14.6






%






 






 






139.8






 






 






 






11.8






%






 






 






117.8






 






 






 






10.7






%








Earnings per share






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 








Basic earnings per common share






 






 






0.17






 






 






 






 






 






 






0.18






 






 






 






 






 






 






0.51






 






 






 






 






 






 






0.43






 






 






 






 








Diluted earnings per common share






 






 






0.17






 






 






 






 






 






 






0.18






 






 






 






 






 






 






0.51






 






 






 






 






 






 






0.43






 






 






 






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 








 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 








Average common shares outstanding






 






 






273.0






 






 






 






 






 






 






272.9






 






 






 






 






 






 






273.0






 






 






 






 






 






 






271.1






 






 






 






 








Average shares assuming dilution






 






 






273.0






 






 






 






 






 






 






272.9






 






 






 






 






 






 






273.0






 






 






 






 






 






 






271.2






 






 






 






 









Reported Segment Information








(Amounts in € millions)








 






 






For the three months ended December 31, 2025






 








 






 






Biopharmaceutical

and Diagnostic

Solutions






 






 






Engineering






 






 






Adjustments,

eliminations and unallocated items






 






 






Consolidated






 








 






 






 






 






 






 






 






 






 






 






 






 






 








External Customers






 






 






307.1






 






 






 






39.4






 






 






 






—






 






 






 






346.5






 








Inter-Segment






 






 






0.2






 






 






 






35.9






 






 






 






(36.1






)






 






 






—






 








Revenue






 






 






307.2






 






 






 






75.3






 






 






 






(36.1






)






 






 






346.5






 








 






 






 






 






 






 






 






 






 






 






 






 






 








Gross Profit






 






 






97.0






 






 






 






11.9






 






 






 






(1.9






)






 






 






106.9






 








Gross Profit Margin






 






 






31.6






%






 






 






15.8






%






 






 






 






 






 






30.9






%








 






 






 






 






 






 






 






 






 






 






 






 






 








Operating Profit






 






 






73.1






 






 






 






6.9






 






 






 






(9.9






)






 






 






70.1






 








Operating Profit Margin






 






 






23.8






%






 






 






9.1






%






 






 






 






 






 






20.2






%









 






 






For the three months ended December 31, 2024






 








 






 






Biopharmaceutical

and Diagnostic

Solutions






 






 






Engineering






 






 






Adjustments,

eliminations and unallocated items






 






 






Consolidated






 








 






 






 






 






 






 






 






 






 






 






 






 






 








External Customers






 






 






279.4






 






 






 






51.2






 






 






 






—






 






 






 






330.6






 








Inter-Segment






 






 






1.1






 






 






 






56.1






 






 






 






(57.2






)






 






 






—






 








Revenue






 






 






280.5






 






 






 






107.3






 






 






 






(57.2






)






 






 






330.6






 








 






 






 






 






 






 






 






 






 






 






 






 






 








Gross Profit






 






 






87.2






 






 






 






20.0






 






 






 






(9.0






)






 






 






98.2






 








Gross Profit Margin






 






 






31.1






%






 






 






18.6






%






 






 






 






 






 






29.7






%








 






 






 






 






 






 






 






 






 






 






 






 






 








Operating Profit






 






 






65.5






 






 






 






16.4






 






 






 






(15.0






)






 






 






66.9






 








Operating Profit Margin






 






 






23.3






%






 






 






15.3






%






 






 






 






 






 






20.2






%









 






 






For the year ended December 31, 2025






 








 






 






Biopharmaceutical

and Diagnostic

Solutions






 






 






Engineering






 






 






Adjustments,

eliminations and unallocated items






 






 






Consolidated






 








 






 






 






 






 






 






 






 






 






 






 






 






 








External Customers






 






 






1,038.2






 






 






 






148.1






 






 






 






—






 






 






 






1,186.3






 








Inter-Segment






 






 






2.2






 






 






 






132.9






 






 






 






(135.1






)






 






 






—






 








Revenue






 






 






1,040.3






 






 






 






281.0






 






 






 






(135.1






)






 






 






1,186.3






 








 






 






 






 






 






 






 






 






 






 






 






 






 








Gross Profit






 






 






328.1






 






 






 






31.0






 






 






 






(15.3






)






 






 






343.9






 








Gross Profit Margin






 






 






31.5






%






 






 






11.0






%






 






 






 






 






 






29.0






%








 






 






 






 






 






 






 






 






 






 






 






 






 








Operating Profit






 






 






220.4






 






 






 






9.3






 






 






 






(31.0






)






 






 






198.8






 








Operating Profit Margin






 






 






21.2






%






 






 






3.3






%






 






 






 






 






 






16.8






%









 






 






For the year ended December 31, 2024






 








 






 






Biopharmaceutical

and Diagnostic

Solutions






 






 






Engineering






 






 






Adjustments,

eliminations and unallocated items






 






 






Consolidated






 








 






 






 






 






 






 






 






 






 






 






 






 






 








External Customers






 






 






933.7






 






 






 






170.3






 






 






 






—






 






 






 






1,104.0






 








Inter-Segment






 






 






4.0






 






 






 






187.3






 






 






 






(191.4






)






 






 






—






 








Revenue






 






 






937.8






 






 






 






357.6






 






 






 






(191.4






)






 






 






1,104.0






 








 






 






 






 






 






 






 






 






 






 






 






 






 








Gross Profit






 






 






268.8






 






 






 






56.2






 






 






 






(22.6






)






 






 






302.3






 








Gross Profit Margin






 






 






28.7






%






 






 






15.7






%






 






 






 






 






 






27.4






%








 






 






 






 






 






 






 






 






 






 






 






 






 








Operating Profit






 






 






165.6






 






 






 






33.1






 






 






 






(37.6






)






 






 






161.1






 








Operating Profit Margin






 






 






17.7






%






 






 






9.3






%






 






 






 






 






 






14.6






%









Cash Flow








(Amounts in € millions)








 








 






 






For the three months

ended December 31,






 






 






For the years

ended December 31,






 








 






 






2025






 






 






2024






 






 






2025






 






 






2024






 








Cash flow from operating activities






 






 






94.1






 






 






 






43.6






 






 






 






286.1






 






 






 






155.8






 








Cash flow used in investing activities






 






 






(94.4






)






 






 






(91.0






)






 






 






(272.9






)






 






 






(310.2






)








Cash flow from financing activities






 






 






17.2






 






 






 






66.3






 






 






 






22.1






 






 






 






183.2






 








Net change in cash and cash equivalents






 






 






16.9






 






 






 






18.9






 






 






 






35.2






 






 






 






28.8






 







Non-GAAP Financial Information


This press release contains non-GAAP financial measures. Please refer to "Non-GAAP Financial Information" and the tables included in this press release for a reconciliation of non-GAAP financial measures.




Reconciliation of Revenue to Constant Currency Revenue








(Amounts in € millions)








 








Three months ended December 31, 2025






 






Biopharmaceutical and

Diagnostic Solutions






 






 






Engineering






 






 






Consolidated






 








Reported Revenue (IFRS GAAP)






 






 






307.1






 






 






 






39.4






 






 






 






346.5






 








Effect of changes in currency translation rates






 






 






8.0






 






 






 






—






 






 






 






8.0






 








Organic Revenue (Non-IFRS GAAP)






 






 






315.1






 






 






 






39.4






 






 






 






354.5






 









Year ended December 31, 2025






 






Biopharmaceutical and

Diagnostic Solutions






 






 






Engineering






 






 






Consolidated






 








Reported Revenue (IFRS GAAP)






 






 






1,038.2






 






 






 






148.1






 






 






 






1,186.3






 








Effect of changes in currency translation rates






 






 






17.7






 






 






 






—






 






 






 






17.7






 








Organic Revenue (Non-IFRS GAAP)






 






 






1,055.9






 






 






 






148.1






 






 






 






1,204.0






 









Reconciliation of EBITDA








(Amounts in € millions)








 








 






 






For the three months

ended December 31,






 






 






Change






 






 






For the years

ended December 31,






 






 






Change






 








 






 






2025






 






 






2024






 






 






%






 






 






2025






 






 






2024






 






 






%






 








Net Profit






 






 






47.6






 






 






 






48.3






 






 






 






(1.6






)%






 






 






139.8






 






 






 






117.8






 






 






 






18.7






%








Income Taxes






 






 






18.2






 






 






 






16.3






 






 






 






11.4






%






 






 






49.3






 






 






 






42.5






 






 






 






15.9






%








Finance Income






 






 






0.3






 






 






 






5.6






 






 






 






(94.3






)%






 






 






13.0






 






 






 






13.5






 






 






 






(3.9






)%








Finance Expenses






 






 






4.6






 






 






 






7.8






 






 






 






(40.8






)%






 






 






22.7






 






 






 






14.3






 






 






 






58.0






%








Operating Profit






 






 






70.1






 






 






 






66.8






 






 






 






4.8






%






 






 






198.8






 






 






 






161.1






 






 






 






23.4






%








Depreciation and amortization and impairment of PPE






 






 






24.6






 






 






 






19.8






 






 






 






24.8






%






 






 






88.6






 






 






 






80.7






 






 






 






9.8






%








EBITDA






 






 






94.7






 






 






 






86.6






 






 






 






9.4






%






 






 






287.4






 






 






 






241.8






 






 






 






18.8






%









Calculation of Net Profit Margin, Operating Profit Margin, Adjusted EBITDA Margin and Adjusted Operating Profit Margin








(Amounts in € millions)








 








 






 






For the three months

ended December 31,






 






 






For the year

ended December 31,






 








 






 






2025






 






 






2024






 






 






2025






 






 






2024






 








Revenue






 






 






346.5






 






 






 






330.6






 






 






 






1,186.3






 






 






 






1,104.0






 








Net Profit Margin (Net Profit/ Revenue)






 






 






13.7






%






 






 






14.6






%






 






 






11.8






%






 






 






10.7






%








Operating Profit Margin (Operating Profit/ Revenue)






 






 






20.2






%






 






 






20.2






%






 






 






16.8






%






 






 






14.6






%








Adjusted EBITDA Margin (Adjusted EBITDA/ Revenue)






 






 






28.2






%






 






 






27.5






%






 






 






25.1






%






 






 






23.5






%








Adjusted Operating Profit Margin (Adjusted Operating Profit/ Revenue)






 






 






21.1






%






 






 






21.5






%






 






 






17.7






%






 






 






16.2






%









Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes,








Net Profit, and Diluted EPS








(Amounts in € millions, except per share data)








 








Three months ended December 31, 2025






 






EBITDA






 






 






Operating Profit






 






 






Income

Taxes (4)






 






 






Net Profit






 






 






Diluted EPS






 








Reported






 






 






94.7






 






 






 






70.1






 






 






 






18.2






 






 






 






47.6






 






 






 






0.17






 








Adjusting items:






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 








Start-up costs new plants (1)






 






 






2.0






 






 






 






2.0






 






 






 






0.5






 






 






 






1.4






 






 






 






0.01






 








Restructuring and related charges (2)






 






 






1.0






 






 






 






1.0






 






 






 






0.3






 






 






 






0.8






 






 






 






0.00






 








Adjusted






 






 






97.7






 






 






 






73.1






 






 






 






19.0






 






 






 






49.8






 






 






 






0.18






 








Adjusted Margin






 






 






28.2






%






 






 






21.1






%






 






 






—






 






 






 






—






 






 






 






—






 









Three months ended December 31, 2024






 






EBITDA






 






 






Operating Profit






 






 






Income Taxes (4)






 






 






Net Profit






 






 






Diluted EPS






 








Reported






 






 






86.6






 






 






 






66.8






 






 






 






16.3






 






 






 






48.3






 






 






 






0.18






 








Adjusting items:






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 








Start-up costs new plants (1)






 






 






3.8






 






 






 






3.8






 






 






 






1.0






 






 






 






2.8






 






 






 






0.01






 








Restructuring and related charges (2)






 






 






0.4






 






 






 






0.4






 






 






 






0.1






 






 






 






0.3






 






 






 






0.00






 








Other severance costs (3)






 






 






0.2






 






 






 






0.2






 






 






 






0.0






 






 






 






0.1






 






 






 






0.00






 








Adjusted






 






 






90.9






 






 






 






71.2






 






 






 






17.5






 






 






 






51.5






 






 






 






0.19






 








Adjusted Margin






 






 






27.5






%






 






 






21.5






%






 






 






—






 






 






 






—






 






 






 






—






 









Year ended December 31, 2025






 






EBITDA






 






 






Operating Profit






 






 






Income Taxes (4)






 






 






Net Profit






 






 






Diluted EPS






 








Reported






 






 






287.4






 






 






 






198.8






 






 






 






49.3






 






 






 






139.8






 






 






 






0.51






 








Adjusting items:






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 








Start-up costs new plants (1)






 






 






6.5






 






 






 






6.5






 






 






 






1.8






 






 






 






4.7






 






 






 






0.02






 








Restructuring and related charges (2)






 






 






4.1






 






 






 






4.1






 






 






 






1.0






 






 






 






3.1






 






 






 






0.01






 








Adjusted






 






 






298.0






 






 






 






209.4






 






 






 






52.1






 






 






 






147.6






 






 






 






0.54






 








Adjusted Margin






 






 






25.1






%






 






 






17.7






%






 






 






—






 






 






 






—






 






 






 






—






 









Year ended December 31, 2024






 






EBITDA






 






 






Operating Profit






 






 






Income Taxes (4)






 






 






Net Profit






 






 






Diluted EPS






 








Reported






 






 






241.8






 






 






 






161.1






 






 






 






42.5






 






 






 






117.8






 






 






 






0.43






 








Adjusting items:






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 








Start-up costs new plants (1)






 






 






13.0






 






 






 






13.0






 






 






 






3.5






 






 






 






9.5






 






 






 






0.04






 








Restructuring and related charges (2)






 






 






4.0






 






 






 






4.0






 






 






 






1.0






 






 






 






3.0






 






 






 






0.01






 








Other severance costs (3)






 






 






0.4






 






 






 






0.4






 






 






 






0.1






 






 






 






0.3






 






 






 






0.00






 








Adjusted






 






 






259.2






 






 






 






178.5






 






 






 






47.1






 






 






 






130.6






 






 






 






0.48






 








Adjusted Margin






 






 






23.5






%






 






 






16.2






%






 






 






—






 






 






 






—






 






 






 






—






 









(1) During the three months and the year ended December 31, 2025, the Group recorded €2.0 million and €6.5 million, respectively, of start-up costs for the new plants in Fishers, Indiana, United States, and in Latina, Italy. During the three months and the year ended December 31, 2024, the Group recorded €3.8 million and €13.0 million, respectively, of start-up costs for the new plants in Fishers, Indiana, United States, and in Latina, Italy. These costs primarily reflect labor expenses for training and travel of personnel who are in the learning and development phase and not yet active in the manufacturing of products, as well as the related recruitment costs.








(2) During the three months and the year ended December 31, 2025, the Group recorded €1.0 million and €4.1 million, respectively, of restructuring and related charges. During the three months and the year ended December 31, 2024, the Group recorded €0.4 million and €4.0 million, respectively, of restructuring and related charges. These amounts mainly reflect employee-related costs associated with the reorganization of certain business functions.








(3) During the three months and the year ended December 31, 2024, the Group recorded €0.2 million and €0.4 million, respectively, related to personnel expenses, including other severance costs.








(4) The income tax adjustment is calculated by multiplying the applicable nominal tax rate to the adjusting items.









Capital Employed








(Amounts in € millions)








 








 






 






As of December 31,

2025






 






 






As of December 31,

2024






 








 






 






 






 






 






 






 








- Goodwill and Other intangible assets






 






 






86.8






 






 






 






83.6






 








- Right of Use assets






 






 






12.4






 






 






 






15.7






 








- Property, plant, and equipment






 






 






1,391.5






 






 






 






1,248.4






 








- Financial assets - investments FVTPL






 






 






0.2






 






 






 






0.2






 








- Other non-current financial assets






 






 






5.5






 






 






 






5.4






 








- Deferred tax assets






 






 






103.9






 






 






 






95.3






 








Non-current assets excluding FV of derivative financial instruments






 






 






1,600.3






 






 






 






1,448.7






 








 






 






 






 






 






 






 








- Inventories






 






 






268.2






 






 






 






245.2






 








- Contract Assets






 






 






180.5






 






 






 






168.5






 








- Trade receivables






 






 






302.7






 






 






 






296.0






 








- Trade payables






 






 






(263.3






)






 






 






(231.0






)








- Advances from customers






 






 






(33.4






)






 






 






(16.6






)








- Non-current advances from customers






 






 






(98.8






)






 






 






(44.0






)








- Contract Liabilities






 






 






(10.4






)






 






 






(16.5






)








Trade working capital






 






 






345.4






 






 






 






401.6






 








 






 






 






 






 






 






 








- Tax receivables and other receivables






 






 






50.6






 






 






 






70.6






 








- Current financial receivables - rent to buy agreement






 






 






8.6






 






 






 






—






 








- Non-current assets held for sale






 






 






—






 






 






 






0.2






 








- Tax payables and other liabilities






 






 






(100.8






)






 






 






(92.2






)








- Current Provisions






 






 






(4.4






)






 






 






(4.1






)








Net working capital






 






 






299.3






 






 






 






376.1






 








 






 






 






 






 






 






 








- Deferred tax liabilities






 






 






(13.3






)






 






 






(12.6






)








- Employees benefits






 






 






(6.8






)






 






 






(7.2






)








- Non-Current Provisions






 






 






(3.2






)






 






 






(2.8






)








- Other non-current liabilities






 






 






(52.1






)






 






 






(62.7






)








Total non-current liabilities and provisions






 






 






(75.4






)






 






 






(85.3






)








 






 






 






 






 






 






 








Capital employed






 






 






1,824.2






 






 






 






1,739.4






 








 






 






 






 






 






 






 








Net (debt)/ net cash






 






 






(337.7






)






 






 






(335.0






)








 






 






 






 






 






 






 








Equity






 






 






(1,486.5






)






 






 






(1,404.4






)








 






 






 






 






 






 






 








Total equity and net debt






 






 






(1,824.2






)






 






 






(1,739.4






)








 






 






 






 






 






 






 









Free Cash Flow








(Amounts in € millions)








 








 






 






For the three months

ended December 31,






 






 






For the years

ended December 31,






 








 






 






2025






 






 






2024






 






 






2025






 






 






2024






 








Cash Flow from Operating Activities






 






 






94.1






 






 






 






43.6






 






 






 






286.1






 






 






 






155.8






 








Interest paid






 






 






2.0






 






 






 






3.6






 






 






 






7.0






 






 






 






7.4






 








Interest received






 






 






(0.2






)






 






 






(0.4






)






 






 






(1.4






)






 






 






(1.3






)








Purchase of property, plant, and equipment






 






 






(89.3






)






 






 






(88.9






)






 






 






(263.8






)






 






 






(302.6






)








Proceeds from sale of property, plant, and equipment






 






 






0.2






 






 






 






—






 






 






 






1.9






 






 






 






3.2






 








Purchase of intangible assets






 






 






(5.2






)






 






 






(2.3






)






 






 






(11.3






)






 






 






(11.0






)








Free Cash Flow






 






 






1.5






 






 






 






(44.3






)






 






 






18.4






 






 






 






(148.5






)









Net (Debt) / Net Cash








(Amounts in € millions)








 








 






 






As of December 31,






 






 






As of December 31,






 








 






 






2025






 






 






2024






 








Non-current financial liabilities






 






 






(347.4






)






 






 






(317.7






)








Current financial liabilities






 






 






(123.5






)






 






 






(116.9






)








Other non-current financial assets - Fair value of derivatives financial instruments






 






 






0.3






 






 






 






—






 








Other current financial assets






 






 






2.2






 






 






 






1.3






 








Cash and cash equivalents






 






 






130.6






 






 






 






98.3






 








Net (Debt)/ Net Cash






 






 






(337.7






)






 






 






(335.0






)









CAPEX








(Amounts in € millions)








 








 






 






For the three months

ended December 31,






 






 






Change






 






 






For the year

ended December 31,






 






 






Change






 








 






 






2025






 






 






2024






 






 






€






 






 






2025






 






 






2024






 






 






€






 








Addition to Property, plants, and equipment






 






 






95.9






 






 






 






77.7






 






 






 






18.2






 






 






 






283.6






 






 






 






275.6






 






 






 






8.0






 








Addition to Intangible Assets






 






 






5.3






 






 






 






2.3






 






 






 






3.0






 






 






 






11.3






 






 






 






11.0






 






 






 






0.3






 








CAPEX






 






 






101.2






 






 






 






80.0






 






 






 






21.2






 






 






 






294.9






 






 






 






286.6






 






 






 






8.3






 









Reconciliation of 2026 Guidance*








Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS








(Amounts in € millions, except per share data)








 








 






 






Revenue






 






EBITDA






 






Operating Profit






 






Net Profit






 






Diluted EPS








Reported






 






1,260.0 - 1,290.0






 






317.7 - 332.9






 






212.7 - 227.8






 






149.6 - 160.7






 






0.55 - 0.59








Adjusting items:






 






 






 






 






 






 






 






 






 






 








Start-up costs new plants






 






 






 






14.1






 






14.1






 






10.3






 






0.04








Adjusted






 






1,260.0 - 1,290.0






 






331.8 - 346.9






 






226.8 - 241.9






 






159.9 - 171.0






 






0.59 - 0.63

















 



*Amounts may not add due to rounding







 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260304625622/en/
Media

Caterina Tripepi

caterina.tripepi@stevanatogroup.com


U.S. Media

Taylor Gerrells

taylor.gerrells@teamlewis.com


Investor Relations

Lisa Miles

lisa.miles@stevanatogroup.com


Giacomo Guiducci

giacomo.guiducci@stevanatogroup.com


Original: Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins